Literature DB >> 18265961

Autoantibodies against opioid or glutamate receptors are associated with changes in morphine reward and physical dependence in mice.

Francesca Capone1, Walter Adriani, Maria Shumilina, Galina Izykenova, Oleg Granstrem, Svetlana Dambinova, Giovanni Laviola.   

Abstract

BACKGROUND: Possible interactions between nervous and immune systems during opioid addiction remain elusive. Recombinant mu-delta opioid receptors (MDOR) and the glutamate receptor 1 (GluR1) subunit of amino-3-hydroxy-5-methyl-4-isoxazole propionic acid glutamate receptors are involved in acute and chronic effects of morphine. Elevated levels of autoantibodies (aAbs) to these receptors were demonstrated in heroin human addicts and in animal models. This study characterized the role of aAbs to these receptors in behavioral modulations recruited during opioid tolerance and sensitization. METHODS AND
FINDINGS: Male CD-1 mice, immunized with either MDOR or GluR1 peptide fragments (80 microg intraperitoneal (i.p.)), were examined for spontaneous behavior and response to morphine (5 mg/kg i.p.). Spontaneous home-cage activity, novelty-induced self-grooming and morphine-induced hyperactivity were higher in GluR1 mice compared to Vehicle subjects, whereas MDOR immunization was associated with an increased morphine-induced conditioned place preference. In response to escalating doses of morphine (from 10 to 60 mg/kg i.p., twice daily) and naloxone-precipitated withdrawal (1 mg/kg subcutaneous), GluR1 mice exhibited a more marked stereotyped sniffing behavior and less body tremors compared to Vehicle subjects, whereas less sniffing and teeth chattering were found in MDOR mice. The expected downregulation of mu receptor binding sites, induced by chronic morphine in vehicle subjects, was completely absent following MDOR immunization.
CONCLUSIONS: These findings indicate an altered response to morphine-related reinforcing and aversive effects in MDOR mice and altered coping with the environment in GluR1 mice. Circulating aAbs to specific neuroreceptors may alter the response to opiates and play a role as determinants of vulnerability to opiate addiction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18265961     DOI: 10.1007/s00213-007-1062-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  76 in total

1.  Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve.

Authors:  I Sora; G Elmer; M Funada; J Pieper; X F Li; F S Hall; G R Uhl
Journal:  Neuropsychopharmacology       Date:  2001-07       Impact factor: 7.853

Review 2.  Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome.

Authors:  Gisele Zandman-Goddard; Joab Chapman; Yehuda Shoenfeld
Journal:  Semin Arthritis Rheum       Date:  2007-01-26       Impact factor: 5.532

3.  Chronic morphine treatment modulates the extracellular levels of endogenous enkephalins in rat brain structures involved in opiate dependence: a microdialysis study.

Authors:  Magdalena Mas Nieto; Jodie Wilson; Annie Cupo; Bernard P Roques; Florence Noble
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

Review 4.  Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence.

Authors:  S M Johnson; W W Fleming
Journal:  Pharmacol Rev       Date:  1989-12       Impact factor: 25.468

5.  AMPA antagonist LY293558 blocks the development, without blocking the expression, of behavioral sensitization to morphine.

Authors:  W A Carlezon; K Rasmussen; E J Nestler
Journal:  Synapse       Date:  1999-03-15       Impact factor: 2.562

Review 6.  Pathogenic autoantibodies to neuronal proteins in neurological disorders.

Authors:  A Vincent; O Lily; J Palace
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

7.  Contrasting grooming phenotypes in C57Bl/6 and 129S1/SvImJ mice.

Authors:  Allan V Kalueff; Pentti Tuohimaa
Journal:  Brain Res       Date:  2004-11-26       Impact factor: 3.252

8.  Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis.

Authors:  S W Rogers; P I Andrews; L C Gahring; T Whisenand; K Cauley; B Crain; T E Hughes; S F Heinemann; J O McNamara
Journal:  Science       Date:  1994-07-29       Impact factor: 47.728

9.  Evidence for addiction-like behavior in the rat.

Authors:  Véronique Deroche-Gamonet; David Belin; Pier Vincenzo Piazza
Journal:  Science       Date:  2004-08-13       Impact factor: 47.728

10.  Evidence that opiate addiction is in part an immune response. Destruction of the immune system by irradiation-altered opiate withdrawal.

Authors:  N Dafny; N R Pellis
Journal:  Neuropharmacology       Date:  1986-08       Impact factor: 5.250

View more
  4 in total

1.  Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation.

Authors:  Henrietta Szutorisz; Jennifer A DiNieri; Eric Sweet; Gabor Egervari; Michael Michaelides; Jenna M Carter; Yanhua Ren; Michael L Miller; Robert D Blitzer; Yasmin L Hurd
Journal:  Neuropsychopharmacology       Date:  2014-01-02       Impact factor: 7.853

Review 2.  Epigenetic Alterations in Prescription Opioid Misuse: New Strategies for Precision Pain Management.

Authors:  Maria Carla Gerra; Cristina Dallabona; Lars Arendt-Nielsen
Journal:  Genes (Basel)       Date:  2021-08-10       Impact factor: 4.096

3.  Immunization with DAT fragments is associated with long-term striatal impairment, hyperactivity and reduced cognitive flexibility in mice.

Authors:  Walter Adriani; Susanne Koot; Sandra Columba-Cabezas; Emilia Romano; Domenica Travaglini; Ruud van den Bos; Oleg Granstrem; Syed F Ali; Giovanni Laviola
Journal:  Behav Brain Funct       Date:  2012-11-28       Impact factor: 3.759

Review 4.  Pediatric Autoimmune Disorders Associated with Streptococcal Infections and Tourette's Syndrome in Preclinical Studies.

Authors:  Chiara Spinello; Giovanni Laviola; Simone Macrì
Journal:  Front Neurosci       Date:  2016-06-30       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.